Navigation Links
Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study
Date:5/24/2011

tors."

Radius also announced today that immediately following the initial closing of the equity financing, it merged with MPM Acquisition Corp. ("MAC"), an unlisted public reporting shell company. The surviving company will be renamed Radius Health, Inc. and will continue to maintain the status of a reporting company with the Securities and Exchange Commission. Radius shareholders will hold 100 percent of the resulting company's equity. Radius Health, Inc. plans to apply for a listing on a national securities exchange upon satisfaction of criteria for an initial listing on the exchange.

In connection with the financing, Radius completed a services agreement with Nordic whereby Nordic will manage the pivotal Phase 3 clinical trial of BA058 Injection. The 18-month study will enroll 2,400 patients and will be conducted in eight countries at 11 centers operated by the Center for Clinical and Basic Research, a leading clinical research organization with extensive experience in global osteoporosis registration studies.

"Osteoporosis is a serious medical condition worldwide for which patients have few options for long-term treatment," said Claus Christiansen, MD, Founder and Chairman of Nordic Bioscience and a world-recognized expert in osteoporosis. "There remains a significant unmet need for new anabolic therapies, which build new bone rather than slow its breakdown. We at Nordic are excited about working with Radius on this Phase 3 study for BA058, which we believe will lead to an important new anabolic therapy for this debilitating condition."

In connection with the financing and the combination with MAC, Martin Muenchbach, PhD, Managing Director of BB Biotech Ventures, joined the Radius Board of Directors, along with three senior industry executives: Alan Auerbach, Founder, President, and CEO of Puma Biotechnology as well as Founder, President, and CEO of Cougar Biotechnology prior to its acquisition by Johnson & Johnson; Kurt Graves, f
'/>"/>

SOURCE Radius
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Webcast Presentation at Upcoming Conferences
2. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
3. Advantagene Announces SPA Agreement With FDA to Launch Phase 3 Trial for Novel Vaccine Aimed at Preventing Prostate Cancer Recurrence
4. Vermillion Announces the Appointment of Bruce Huebner to its Board of Directors
5. Ontario Institute for Cancer Research Announces Spin Off Companies Developing Promising Anticancer Technologies
6. ShangPharma Announces First Quarter 2011 Results
7. BioSpecifics Technologies Corp. Announces Data Presentations at Upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting
8. Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
9. Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA
10. ACT Announces Oregon Health & Science University as Clinical Trial Site for its Phase 1/2 Clinical Trial Using hESC-Derived RPE Cells for Macular Degeneration
11. InterMune Announces Presentation of Positive Pirfenidone Data at the International Conference of the American Thoracic Society (ATS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Aug. 1, 2014 One of the major ... personalized medicine, which is the practice of using genomic ... a patient,s individual biology. Personalized diagnostics—laboratory analyses that inform ... in the lab,s future. This fall, AACC ,s ... latest science in this exciting field and the novel ...
(Date:8/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its ... MARKETS , that the global market RNA interference (RNAi) ... $38.8 billion by 2018, with a five-year compound annual ... the fastest moving segment of the market, is moving ... RNAi therapeutics has shown tremendous growth and has moved ...
(Date:7/31/2014)... (PRWEB) August 01, 2014 ... China Polyurethane Resin Industry” is a professional ... market. The report introduces Polyurethane Resin basic ... industry chain structure and industry overview. This ... China’s domestic market as well as global ...
(Date:7/31/2014)... see through organs and even the entire body to ... cellular structures has been a long-time dream of biologists. ... 31st in the journal Cell has now ... making opaque organs, bodies, and human tissue biopsies transparent, ... protocols could pave the way for a better understanding ...
Breaking Biology Technology:First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 4See-through organs and bodies will accelerate biomedical discoveries 2
... , SAN FRANCISCO, Aug. 11 ... stage biopharmaceutical company developing a proprietary breakthrough class of targeted ... private placement financing with gross proceeds of US $5,123,521, exceeding ... anticipated on or before September 15, 2009, with additional proceeds ...
... , , CAMBRIDGE, Mass., Aug. 11 ... of novel therapies for immune-mediated diseases, today announced changes to the protocol ... and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with ... ( D urable Response Therapy E valuation F or ...
... SEATTLE, Aug. 11 Omeros Corporation today announced ... OMS302, the Company,s ophthalmologic PharmacoSurgery(TM) product candidate. OMS302 is ... agent that causes pupil dilation (mydriasis), each with well-known ... Omeros, Phase 1/Phase 2 trial enrolled 61 patients undergoing ...
Cached Biology Technology:Jennerex Closes $5 Million First Tranche of Series C Financing 2Tolerx Announces Amendment to Phase 3 DEFEND Protocol 2Tolerx Announces Amendment to Phase 3 DEFEND Protocol 3Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery 2
(Date:7/31/2014)... enormous conflagration known as the Rim Fire was in ... mature trees, when it entered the backcountry of Yosemite ... 2013. But inside the park, the battle began to ... decisions and drought can combine to fuel large, severe ... it eventually encountered lands where fire had been used ...
(Date:7/31/2014)... are familiar with Hibiscus flowers- they are an ... are commonly planted in the landscape. Some, like ... endangered species. , Only a relatively few botanists ... an equally beautiful and intriguing related group of ... of Hibiscus". , Brother of Hibiscus species are ...
(Date:7/31/2014)... White, brown and beige adipocytes, or fat cells, are ... functions and each plays its own role in metabolism. ... far the most prevalent. Its primary function is energy ... energy to generate heat but are only found in ... adipocytes, which represent a special type of brown adipocytes, ...
Breaking Biology News(10 mins):The Rim Fire 1 year later: A natural experiment in fire ecology and management 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 3The Rim Fire 1 year later: A natural experiment in fire ecology and management 4The Rim Fire 1 year later: A natural experiment in fire ecology and management 5Brother of Hibiscus is found alive and well on Maui 2Hope for the overweight 2
... Washington, DC Engineered nanoscale materials (ENMs), which ... use in food packaging, raise new safety evaluation ... report released today by the Project on Emerging ... The food-packaging industry, food companies and ...
... developed an effective technology for reducing contamination of dangerous ... Salmonella and E. coli O157:H7 on foods ranging from ... It is made from inexpensive and readily available ingredients ... and Drug Administration. The new technology, which ...
... Almost every June for 30 years, Terry McEneaney drove around ... three routes. Park ornithologist at the time, he would ... Then he,d drive another half mile, repeat the process and ... for the North American Breeding Bird Survey. Trying to finish ...
Cached Biology News:Use of nanomaterials in food packaging poses regulatory challenges 2New UGA invention effectively kills foodborne pathogens in minutes 2Bird watchers, space technology come together in Montana State University study 2Bird watchers, space technology come together in Montana State University study 3
Recombinant Rhesus Macaque IFN-alpha...
chk 1 kinase...
...
KNP-1 (HES1) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 35, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
Biology Products: